The House of Representatives, on Thursday, voted 230-192 to pass Speaker Nancy Pelosi’s, D-California, HR 3, the Elijah E. Cummings Lower Drug Costs Now Act, although the White House has already said it will veto the measure, assuming it is ever brought to the Senate floor and passes.
The House of Representatives, on Thursday, voted 230-192 to pass Speaker Nancy Pelosi’s, D-California, HR 3, the Elijah E. Cummings Lower Drug Costs Now Act, although the White House has already said it will veto the measure, assuming it is ever brought to the Senate floor and passes.
Legislators debated for hours Wednesday night and Thursday morning on what has the potential to be a complete overhaul in US prescription drug pricing.
For the first time, HHS would have the ability to allow Medicare to negotiate certain drug prices and seek rebates from drug makers if their prices soar above inflation.
The secretary of HHS would be authorized annually to negotiate prices for up to 250 of the most costly drugs that lack a generic or biosimilar competitor, including both Part D and Part B. Insulin would have been included as well, and Wednesday night, some Democratic representatives talked about the impact insulin pricing has had on their constituents.
On the other side of the aisle, Republican lawmakers advocated instead for HR 19, the Lower Costs, More Cures Act, and said that HR 3 would reduce pharmaceutical and biotech innovation, even possible cures.
The lawmakers were referring to an October Congressional Budget Office preliminary estimate that if HR 3 becomes law, between 8 and 15 fewer drugs would come to market over 10 years.
In a post earlier this month, however, PolitiFact, a nonprofit, nonpartisan news organization, pointed out that the FDA approves about 30 new drugs, on average, annually—or 300 new drugs over 10 years. Over time, the loss of new therapeutics would be perhaps 5%, if there were 15 fewer drugs out of 300 projected approvals. In addition, there has been no analysis about the clinical value of these potential future drugs that might not ever come to market.
HR 3 was supported by organizations like the AARP.
“High drug prices disproportionately hurt older Americans, who take an average of four to five prescription medications each month. The average annual price of a single specialty drug now costs $79,000. Medicare beneficiaries have modest median annual incomes of just over $26,000. Medications cannot help you if you cannot afford them,” said Nancy LeaMonde, AARP’s executive vice president and chief advocacy and engagement officer, in a statement Wednesday.
HR 3 will assign penalties to drug companies that refuse to negotiate with HHS on pricing. It would also require drug makers to pay rebates to Medicare if they hike their prices beyond the increase in inflation, and cap what seniors pay out of pocket for their medications to $2000 a year.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.